Evidence map›Paper›PMID 35967323›Full record

ArticleFrontiers in immunology2022

Human surfactant protein D facilitates SARS-CoV-2 pseudotype binding and entry in DC-SIGN expressing cells, and downregulates spike protein induced inflammation.

Nazar Beirag, Chandan Kumar, Taruna Madan, Mohamed H Shamji, Roberta Bulla, Daniel Mitchell, Valarmathy Murugaiah, Martin Mayora Neto, Nigel Temperton, Susan Idicula-Thomas and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Review
  3. Innate Immune Response to Viral Infection.Advances in experimental medicine and biology · 2025
    Review
  4. Collectins and Ficolins.Advances in experimental medicine and biology · 2025
    Review
  5. Secondary Sites of the C-type Lectin-Like Fold.Chemistry (Weinheim an der Bergstrasse, Germany) · 2024
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Nazar BeiragBiosciences, College of Health, Medicine and Life Sciences, Brunel University London, Uxbridge, United Kingdom.
Chandan KumarBiomedical Informatics Centre, National Institute for Research in Reproductive and Child Health, ICMR, Mumbai, Maharashtra, India.
Taruna MadanDepartment of Innate Immunity, National Institute for Research in Reproductive and Child Health, ICMR, Mumbai, India.
Mohamed H ShamjiImmunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute and NIHR Biomedical Research Centre, Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, London, United Kingdom.
Roberta BullaDepartment of Life Sciences, University of Trieste, Trieste, Italy.
Daniel MitchellWMS - Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, United Kingdom.
Valarmathy MurugaiahBiosciences, College of Health, Medicine and Life Sciences, Brunel University London, Uxbridge, United Kingdom.
Martin Mayora NetoViral Pseudotype Unit, Medway School of Pharmacy, University of Kent and Greenwich, United Kingdom.
Nigel TempertonViral Pseudotype Unit, Medway School of Pharmacy, University of Kent and Greenwich, United Kingdom.
Susan Idicula-ThomasBiomedical Informatics Centre, National Institute for Research in Reproductive and Child Health, ICMR, Mumbai, Maharashtra, India.
Praveen M VargheseBiosciences, College of Health, Medicine and Life Sciences, Brunel University London, Uxbridge, United Kingdom.
Uday KishoreBiosciences, College of Health, Medicine and Life Sciences, Brunel University London, Uxbridge, United Kingdom.
Brunel University of London · GBNational Institute for Research in Reproductive Health · INMedway School of Pharmacy · GBImperial College London · GBUniversity of Trieste · ITUniversity of Warwick · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

Lung surfactant protein D (SP-D) and Dendritic cell-specific intercellular adhesion molecules-3 grabbing non-integrin (DC-SIGN) are pathogen recognising C-type lectin receptors. SP-D has a crucial immune function in detecting and clearing pulmonary pathogens; DC-SIGN is involved in facilitating dendritic cell interaction with naïve T cells to mount an anti-viral immune response. SP-D and DC-SIGN have been shown to interact with various viruses, including SARS-CoV-2, an enveloped RNA virus that causes COVID-19. A recombinant fragment of human SP-D (rfhSP-D) comprising of α-helical neck region, carbohydrate recognition domain, and eight N-terminal Gly-X-Y repeats has been shown to bind SARS-CoV-2 Spike protein and inhibit SARS-CoV-2 replication by preventing viral entry in Vero cells and HEK293T cells expressing ACE2. DC-SIGN has also been shown to act as a cell surface receptor for SARS-CoV-2 independent of ACE2. Since rfhSP-D is known to interact with SARS-CoV-2 Spike protein and DC-SIGN, this study was aimed at investigating the potential of rfhSP-D in modulating SARS-CoV-2 infection. Coincubation of rfhSP-D with Spike protein improved the Spike Protein: DC-SIGN interaction. Molecular dynamic studies revealed that rfhSP-D stabilised the interaction between DC-SIGN and Spike protein. Cell binding analysis with DC-SIGN expressing HEK 293T and THP- 1 cells and rfhSP-D treated SARS-CoV-2 Spike pseudotypes confirmed the increased binding. Furthermore, infection assays using the pseudotypes revealed their increased uptake by DC-SIGN expressing cells. The immunomodulatory effect of rfhSP-D on the DC-SIGN: Spike protein interaction on DC-SIGN expressing epithelial and macrophage-like cell lines was also assessed by measuring the mRNA expression of cytokines and chemokines. RT-qPCR analysis showed that rfhSP-D treatment downregulated the mRNA expression levels of pro-inflammatory cytokines and chemokines such as TNF-α, IFN-α, IL-1β, IL- 6, IL-8, and RANTES (as well as NF-κB) in DC-SIGN expressing cells challenged by Spike protein. Furthermore, rfhSP-D treatment was found to downregulate the mRNA levels of MHC class II in DC expressing THP-1 when compared to the untreated controls. We conclude that rfhSP-D helps stabilise the interaction between SARS- CoV-2 Spike protein and DC-SIGN and increases viral uptake by macrophages

Indexed as

COVID-19Pulmonary Surfactant-Associated Protein DAngiotensin-Converting Enzyme 2AnimalsCell Adhesion MoleculesChemokinesChlorocebus aethiopsCytokinesDC-Specific ICAM-3 Grabbing NonintegrinHEK293 CellsHumansInflammationLectins, C-TypeReceptors, Cell SurfaceRNA, MessengerSARS-CoV-2Angiotensin-Converting Enzyme 2Cell Adhesion MoleculesChemokinesCytokinesDC-Specific ICAM-3 Grabbing NonintegrinLectins, C-TypePulmonary Surfactant-Associated Protein DReceptors, Cell SurfaceRNA, MessengerSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2collectinsCOVID-19cytokine responseinnate immune systemrfhSP-DSARS-CoV-2

Identifiers

PMID35967323
PMCPMC9367475
OpenAlexW4288425389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.